BTMD vs MGX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BTMD shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Mixed signals with both opportunities and risks present.
MGX exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company suffers from a catastrophic negative gross margin (-274.58%) and a significant decline in year-over-year revenue (-59.30%), suggesting a failing or highly inefficient business model. While the current ratio of 7.22 provides a temporary liquidity cushion, the combination of bearish insider selling by the CEO and CFO and a 0/100 technical trend suggests a lack of confidence in near-term recovery. Despite a high analyst target price of $9.33, the deterministic data points to a high-risk speculative asset in a downward spiral.
Compare Another Pair
Related Comparisons
BTMD vs MGX: Head-to-Head Comparison
This page compares biote Corp. (BTMD) and Metagenomi Therapeutics, Inc. (MGX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.